Skip to main content
      A biomarker for CV disease in RA?

      Anti-CXCR3 antibodies asso w/ atherosclerosis

      Confirmed in a validation cohort

      Ad

      Aurelie Najm AurelieRheumo

      1 week 3 days ago
      A biomarker for CV disease in RA? Anti-CXCR3 antibodies asso w/ atherosclerosis Confirmed in a validation cohort Adding Ab profile to the mSCORE increases AUC from 0.6 to 0.9 Sens from 30 to 69% How does it compare with other ways of detecting atherosclerosis? #POS0899 https://t.co/O7bsLrVyzo
      Can we have an effective, comprehensive score for
      #SLE #arthritis?

      #SLEDAI has a problem
      SJC>2 scores dames as ex #S

      Janet Pope Janetbirdope

      1 week 3 days ago
      Can we have an effective, comprehensive score for #SLE #arthritis? #SLEDAI has a problem SJC>2 scores dames as ex #SJC=12 Meet #LAMBDA An attempt to improve a true positive #MSK OUTCOME in #lupus Needs validation esp in pts over time #EULAR2026 @RheumNow #POS1072 @eular_org https://t.co/fr0xuVqFnM
      #EULAR2026 POS0306 Can we predict #lupus nephritis pts who would achieve CR at 12 mths? Monocentric study used M.Learnin

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week 3 days ago
      #EULAR2026 POS0306 Can we predict #lupus nephritis pts who would achieve CR at 12 mths? Monocentric study used M.Learning: developed & internally validated 5 Clinical Score (LUPRED) with AUC 0.75 training set, 0.78 validation. Simple to use but needs external validation @RheumNow https://t.co/1VRE1yBCac
      There are so many SLE trials, and over the last year, many new ideas have been suggested.
      #EULAR2026 POS0713 Is there a hope for BTK-inhibition in #SLE despite several previous failures? A Phase IIb RCT in Chin

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week 3 days ago
      #EULAR2026 POS0713 Is there a hope for BTK-inhibition in #SLE despite several previous failures? A Phase IIb RCT in China: primary endpoint (SRI-4) was met in Orelabrutinib vs PBO in dose-dependent manner. No new safety signal. Phase 3 RCT is underway @RheumNow https://t.co/4cJ8ezppTS
      #proof of #concept in #Sjogren’s #dis

      #lanalumab Treatment reduced in #SjD
      ✅reduced B cells in #salivary #glands
      ?

      Janet Pope Janetbirdope

      1 week 3 days ago
      #proof of #concept in #Sjogren’s #dis #lanalumab Treatment reduced in #SjD ✅reduced B cells in #salivary #glands —nearly complete depletion in serum ✅reduced B cell activation ✅improved #inflammation of #parotid & #submandibular glands @RheumNow #EULAR2026 #OP0163 #POS0284
      Updates in SLE and APS
      • 2026 EULAR Press Release
      Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) often overlap. While there have been some therapeutic advances, significant needs remain around diagnosis and monitoring, with a gap around definitions and biomarkers for refractory disease or specific subsets. EULAR – The European Alliance of Associations for Rheumatology – held its 2026 annual Congress in London, where new data showcased advances in the field. 
      Interim results from ASTER, a study on real world effectiveness of ANI in SLE: Pts receiving ANI had improvements in to

      sheila RHEUMarampa

      1 week 3 days ago
      Interim results from ASTER, a study on real world effectiveness of ANI in SLE: Pts receiving ANI had improvements in total SLEDAI-2K scores after 1 yr ffup period MCT, MSK & hema had the highest decrease in SLEDAI-2K scores from pre-tx to 1yr ffup OP342 @RheumNow #EULAR2026 https://t.co/DArOwQtxM6
      #EULAR2026 POS0156 “TWO’S company, THREE’S a crowd” Tri-specific CD19/CD3/CD28 (i.e. CD28 co-stimulates Tcell ac

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week 3 days ago
      #EULAR2026 POS0156 “TWO’S company, THREE’S a crowd” Tri-specific CD19/CD3/CD28 (i.e. CD28 co-stimulates Tcell activation) TriTE via IV showed early efficacy & safety in 11 #SLE patients up to 48WKS. Longer FU needed to see if repeat dosing needed @RheumNow https://t.co/FpXzJIYwZF
      #OP0342 Interim real-world ASTER data showed anifrolumab improved overall SLEDAI-2K scores & reduced disease activit

      Mrinalini Dey DrMiniDey

      1 week 3 days ago
      #OP0342 Interim real-world ASTER data showed anifrolumab improved overall SLEDAI-2K scores & reduced disease activity across multiple organ systems over 12 months, particularly mucocutaneous & MSK domains. Nearly 30% achieved SLEDAI-2K=0 at 1 year. #EULAR2026 @RheumNow https://t.co/IJlDnHSTh2
      #OP0336 Exploratory analyses from REGENCY👑OBI +standard tx induced ⬆️ histological remission & markedly gre

      Mrinalini Dey DrMiniDey

      1 week 3 days ago

      #OP0336 Exploratory analyses from REGENCY👑 OBI +standard tx induced ⬆️ histological remission & markedly greater kidney tissue B-cell depletion vs PBO in lupus nephritis. Many patients without clinical CRR still achieved histologic remission. #EULAR2026 @RheumNow #EULARBest https://t.co/DoOlRO9QsC

      #OP0340 Long-term DARALUP data suggest CD38-targeting with daratumumab may be promising in refractory SLE, with rapid se

      Mrinalini Dey DrMiniDey

      1 week 3 days ago
      #OP0340 Long-term DARALUP data suggest CD38-targeting with daratumumab may be promising in refractory SLE, with rapid serologic and clinical improvements sustained to 84 weeks in many patients. Flares occurred in 6/10 patients but responded to belimumab. #EULAR2026 @RheumNow
      Post marketing safety signals of anifrolumab from US FDA adverse event reporting system - herpes zoster significantly as

      Bella Mehta bella_mehta

      1 week 3 days ago
      Post marketing safety signals of anifrolumab from US FDA adverse event reporting system - herpes zoster significantly associated. Others include infusion reactions and intermittent hypersensitivity @RheumNow ##EULAR2026 #POS1067
      ×